Abstract
Introduction Functional magnetic resonance imaging (fMRI) studies examining cue-reactivity in cannabis use disorder (CUD) to date have either involved non-treatment seeking participants or been small. We addressed this gap by administering an fMRI cue-reactivity task to CUD participants entering two separate clinical trials.
Methods Treatment-seeking participants with moderate or severe CUD had behavioral craving measured at baseline via the Marijuana Craving Questionnaire (MCQ-SF). They additionally completed a visual cannabis cue-reactivity paradigm during fMRI following 24-hours of abstinence from cannabis. During fMRI, the Blood Oxygen Level Dependent (BOLD) signal was acquired while participants viewed cannabis-images or matched-neutral-images. BOLD responses were correlated with the MCQ-SF using a General Linear Model.
Results N=65 participants (32% female; mean age 30.4±9.9SD) averaged 46.3±15.5SD on the MCQ-SF. When contrasting cannabis-images vs. matched-neutral-images, participants showed greater BOLD response in bilateral ventromedial prefrontal, dorsolateral prefrontal, anterior cingulate, and visual cortices, as well as the striatum. Similarly, there was stronger task-based functional-connectivity (tbFC) between the medial prefrontal cortex and both the amygdala and the visual cortex. There were no significant differences in either activation or tbFC between studies or between sexes. Craving negatively correlated with BOLD response in the left ventral striatum (R2=-0.25; p=0.01).
Conclusions We found that, among two separate treatment-seeking CUD groups, cannabis cue-reactivity was evidenced by greater activation and tbFC in regions related to executive function and reward processing, and craving was negatively associated with cue-reactivity in the ventral striatum. Future directions include examining if pharmacological, neuromodulatory, or psychosocial interventions can alter corticostriatal cue-reactivity.
Competing Interest Statement
GLS has collaborated with MagVenture and MECTA as part of investigator-initiated trials, consults for and has equity in the company Trial Catalyst, has provided consultation to Indivior, and is a named inventor on Stanford owned intellectual property (provisional patent 63/592,527). KMG has provided consultation to Indivior and Jazz Pharmaceuticals and has received research support from Aelis Farma. ALM has received research support from PleoPharma and has provided consultation to Indivior. None of the other authors have any relevant conflicts to disclose.
Clinical Trial
NCT02892110, NCT03144232
Funding Statement
This work was supported by the National Institutes of Health, Grant numbers: K23DA043628 (PI: Sahlem, NIH/NIDA), K12DA031794 (Co-PI's McRae-Clark and Gray, NIH/NIDA), K24DA038240 (PI: McRae-Clark, NIH/NIDA), UG3DA043231 (Co-PI's McRae-Clark and Gray, NIH/NIDA), K23AA025399 (PI: Squeglia NIH/NIAAA), K23DA045099 (PI Sherman, NIH/NIDA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All research related activities were approved by the Medical University of South Carolina's Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of Interests: GLS has collaborated with MagVenture and MECTA as part of investigator-initiated trials, consults for and has equity in the company Trial Catalyst, has provided consultation to Indivior, and is a named inventor on Stanford owned intellectual property (provisional patent 63/592,527). KMG has provided consultation to Indivior and Jazz Pharmaceuticals and has received research support from Aelis Farma. ALM has received research support from PleoPharma and has provided consultation to Indivior. None of the other authors have any relevant conflicts to disclose.
Funding source: This work was supported by the National Institutes of Health, Grant numbers: K23DA043628 (PI: Sahlem, NIH/NIDA), K12DA031794 (Co-PI’s McRae-Clark and Gray, NIH/NIDA), K24DA038240 (PI: McRae-Clark, NIH/NIDA), UG3DA043231 (Co-PI’s McRae-Clark and Gray, NIH/NIDA), K23AA025399 (PI Squeglia NIH/NIAAA), K23DA045099 (PI Sherman, NIH/NIDA).
Clinicaltrials.gov identifiers: NCT02892110, NCT03144232.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
